Silodosin
Title: Silodosin
CAS Registry Number: 160970-54-7
CAS Name: 2,3-Dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1H-indole-7-carboxamide
Manufacturers' Codes: KMD-3213
Molecular Formula: C25H32F3N3O4
Molecular Weight: 495.53
Percent Composition: C 60.60%, H 6.51%, F 11.50%, N 8.48%, O 12.91%
Literature References: a1a-Adrenoceptor antagonist. Prepn: M. Kitazawa et al., EP 600675; eidem, US 5387603 (1994, 1995 both to Kissei). Adrenoceptor binding study: K. Shibata et al., Mol. Pharmacol. 48, 250 (1995); and tissue selectivity: S. Murata et al., J. Urol. 164, 578 (2000). Pharmacology: K. Akiyama et al., Pharmacology 64, 140 (2002). Series of articles on pharmacology, pharmacokinetcs and toxicology: Yakugaku Zasshi 126, 187-263 (2006). Review of development and therapeutic potential: F. Kamali, Curr. Opin. Cent. Peripher. Nerv. Syst. Invest. Drugs 1, 248-252 (1999).
Properties: [a]D25 -14.0° (c = 1.01 in methanol).
Optical Rotation: [a]D25 -14.0° (c = 1.01 in methanol)
Therap-Cat: In treatment of benign prostatic hypertophy.
Keywords: a-Adrenergic Blocker.

Others monographs:
Phosphorus TribromideCyproquinateEthyl MethanesulfonateMethafurylene
Zinc PermanganatePemetrexed3,5-DiiodotyrosineAllopregnane-3β,11β,21-triol-20-one
DexamethasoneThalidomideCyclopropaneSampatrilat
NornidulinSancyclineIsrapafant2-Ethoxyethanol
©2016 DrugLead US FDA&EMEA